Levels of 17β-hydroxysteroid dehydrogenase type 10 in CSF are not a valuable biomarker for multiple sclerosis

• Published in: Biomarkers in medicine 2018-12, Vol.12 (12), p.1331-1340
• Main Authors: Kristofikova, Zdenka, Ricny, Jan, Kaping, Daniel, Klaschka, Jan, Kotoucova, Jolana, Bartos, Ales
• Format: Article
• Language: English
• Subjects: 17β-hydroxysteroid dehydrogenase type 10; 3-Hydroxyacyl CoA Dehydrogenases - cerebrospinal fluid; Adult; Alzheimer's disease; Amyloid; Amyloid beta-Peptides - cerebrospinal fluid; Animal cognition; Axons; Biomarkers; Biomarkers - cerebrospinal fluid; Cerebrospinal fluid; CSF biomarkers; cyclophilin D; Cytokines; Dehydrogenases; Deoxyribonucleic acid; diagnosis; DNA; Female; Humans; Immune system; Leukocytes; Male; Metabolism; Mitochondria; mitochondrial dysfunction; Multiple sclerosis; Multiple Sclerosis - cerebrospinal fluid; Neurodegeneration; neuroinflammation; parkin; Peptide Fragments - cerebrospinal fluid; Peptides; Phosphatase; protein interactions; Proteins
• ISSN: 1752-0363; 1752-0371
• DOI: 10.2217/bmm-2018-0061

We aimed to characterize the role of mitochondrial 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) overexpression in multiple sclerosis (MS) and to evaluate its use as a biomarker. We estimated levels of 17β-HSD10, amyloid β 1-42, cyclophilin D, 17β-HSD10-cyclophilin D complexes or 17β-HSD10-parkin complexes in cerebrospinal fluid (CSF) samples. The increase in 17β-HSD10 levels or in 17β-HSD10-parkin complexes and links to leukocytes were found only in relapsing-remitting MS. The sensitivity of the biomarker was 64%, the specificity equaled 60-63% compared with controls. Increased CSF levels of 17β-HSD10 in later stages of MS could be interpreted via its upregulation in demyelinated neuronal axons. CSF levels of 17β-HSD10 are not the valuable biomarker for the early diagnosis or for the progression of MS.